RxDoctor Payments Data

Megan Vaughn, PA

Medical · Suffolk, VANPI 1619418548

Payments from drug & device makers

$4,553in general payments, 2019–2025

Across 247 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$564
  • Teva Pharmaceuticals USA, Inc.$421
  • Otsuka America Pharmaceutical, Inc.$393
  • Supernus Pharmaceuticals, Inc.$287
  • Alkermes, Inc.$211
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,553100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,553 in reported general payments places this provider in the 85th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$19,959
Medicare patients
65
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine12$103,234
VraylarCariprazine Hcl18$24,394
Divalproex Sodium44$2,629
Methylphenidate Er (La)Methylphenidate Hcl11$2,492
Lurasidone Hcl12$1,659
Olanzapine25$1,434
Methylphenidate ErMethylphenidate Hcl12$1,264
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine38$1,150
Aripiprazole51$1,051
Divalproex Sodium ErDivalproex Sodium21$900
Venlafaxine Hcl ErVenlafaxine Hcl57$810
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$806
Buspirone Hcl56$710
Trazodone Hcl126$700
Duloxetine Hcl44$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$421$103,23412 claims
AbbVieVraylar$564$24,39418 claims
Almatica Pharma LLCSertraline Hcl$57$25759 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 632 medical providers in Virginia.

Other medical in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →